Idaho Secures $17.85M Settlement Over Generic Drug Price-Fixing

State AG says Idaho families overpaid for necessary medications due to alleged conspiracy.

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Idaho Attorney General Raúl Labrador has joined a coalition of 48 states and territories in announcing $17.85 million in settlements with pharmaceutical companies Lannett Company, Inc. and Bausch Health US, LLC, along with Bausch Health Americas, Inc. The settlements resolve allegations that the companies took part in long-running, nationwide conspiracies to artificially inflate prices, limit competition, and restrain trade for numerous generic prescription drugs.

Why it matters

The settlements are part of a broader effort by states to hold pharmaceutical companies accountable for alleged price-fixing schemes that have forced consumers and businesses to pay inflated costs for necessary medications. Idaho is one of the few states to also secure restitution for affected businesses as part of these agreements.

The details

As part of the settlements, Lannett and Bausch have committed to cooperating with ongoing multistate litigation against 30 corporate defendants and 25 individual executives. The companies also agreed to implement internal reforms aimed at ensuring compliance with antitrust laws and promoting fair competition.

  • The settlements follow previous agreements with Apotex and Heritage totaling $49.1 million.
  • The first trial in the generic drug price-fixing cases is expected to take place in Connecticut in late 2026.

The players

Raúl Labrador

The Idaho Attorney General who announced the settlements.

Lannett Company, Inc.

One of the pharmaceutical companies that settled allegations of price-fixing and anticompetitive behavior.

Bausch Health US, LLC

One of the pharmaceutical companies that settled allegations of price-fixing and anticompetitive behavior.

Bausch Health Americas, Inc.

One of the pharmaceutical companies that settled allegations of price-fixing and anticompetitive behavior.

Got photos? Submit your photos here. ›

What they’re saying

“These drug companies conspired to rig prices and eliminate competition, forcing Idaho families to pay artificially inflated costs for necessary medications.”

— Raúl Labrador, Idaho Attorney General (ktvb.com)

What’s next

The first trial in the generic drug price-fixing cases is expected to take place in Connecticut in late 2026.

The takeaway

The settlements highlight the ongoing efforts by state attorneys general to hold pharmaceutical companies accountable for alleged anticompetitive practices that have driven up the costs of necessary medications for consumers and businesses. Idaho's success in securing restitution for affected businesses is a notable outcome of these efforts.